Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Affimed NV
AFMDAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. Address: Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165
Analytics
Precio Objetivo de WallStreet
24.15 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave AFMD
Análisis de dividendos AFMD
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout AFMD
Valoración de la acción AFMD
Finanzas AFMD
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |